Stock Catalyst Calendar

Below is a Stock Catalyst Calendar with upcoming Events/Catalyst for stocks.

Feb 2019, we are currently in the process of gathering information on biotech, earnings, and other stock catalyst that could impact stock price movement.

You are welcomed to contact us with a catalyst you would like to share – use the Catalyst Contact form.

Sun Mon Tue Wed Thu Fri Sat
1
2
3
4
5
6
7
FOLD Amicus Therapeutics – Phase 1/2 preliminary data at WORLDSymposium
FOLD Amicus Therapeutics – Phase 1/2 preliminary data at WORLDSymposium
Feb 7 – Feb 8 all-day
FOLD Amicus Therapeutics announced that four oral presentations and eight posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 15th Annual WORLDSymposium 2019, to be[...]
8
JNJ – Johnson & Johnson PDUFA for Esketamine
JNJ – Johnson & Johnson PDUFA for Esketamine
Feb 8 – Mar 4 all-day
JNJ - Johnson & Johnson PDUFA for Esketamine
JNJ – Johnson & Johnson PDUFA for Esketamine, Treatment resistant depression is expected by March 3-4, 2019. FDA Advisory Committee Meeting February 12, 2019. Meeting notes likely out February 8,[...]
9
10
11
12
13
MTFB Motif Bio PDUFA Iclaprim
MTFB Motif Bio PDUFA Iclaprim
Feb 13 all-day
MTFB Motif Bio PDUFA Iclaprim
On Aug. 14, 2018 Motif Bio plc $MTFB, a clinical-stage biopharmaceutical company specializing in developing novel antibiotics announced that the FDA had accepted their filing of the New Drug Application[...]
14
15
16
17
18
19
20
21
22
AIMT Aimmune Therapeutics to present data on AR101 at AAAAI Annual Meeting
AIMT Aimmune Therapeutics to present data on AR101 at AAAAI Annual Meeting
Feb 22 – Feb 25 all-day
$AIMT Aimmune Therapeutics to present data on AR101 at AAAAI Annual Meeting. In a press release AIMT said that it will “present data on AR101, oral immunotherapy, and peanut allergy[...]
23
24
Incyte Corporation INCY PDUFA priority review
Incyte Corporation INCY PDUFA priority review
Feb 24 – Feb 25 all-day
Incyte Corporation INCY PDUFA priority review
Incyte Corporation $INCY has PDUFA priority review for Ruxolitinib Graft versus host disease on February 24, 2019. See Press Release: stocksnewsfeed.com/stocks-news-feed/results-of-reach1-study-of-ruxolitinib-jakafi-for-the-treatment-of-acute-graft-versus-host-disease-demonstrate-rapid-and-durable-patient-benefit/
25
26
27
28